To cure cancer and save lives with our innovative
and widely accessible immunotherapies.
Tessa’s story started over 30 years ago, when Dr. Malcolm Brenner, our co-founder, and his team at Baylor College of Medicine embarked on a journey to better understand and harness the body’s natural anti-viral immune response as a therapy for cancer treatment. Their research led to the development of our core platform technology, which uses a type of immune cells known as Virus-Specific T cells (VSTs). Early VST studies have shown early efficacy and a strong safety profile in the treatment of cancer.
Leveraging on these promising data, Tessa initiated a Phase II clinical trial for TT10, a VST therapy targeting nasopharyngeal cancer (NPC), at National Cancer Centre Singapore (NCCS), which produced the best published 2-year survival data in patients with advanced NPC. The trial results set the stage for a Phase III trial – the world’s largest T cell therapy trial for any cancer indication with 330 patients across 30 hospitals in 5 countries .
Today, Tessa is building a portfolio of next-generation therapies targeting a wide range of cancer indications, by combining VSTs with other immuno-oncology approaches. We are proud to be spearheading innovation in the field of cancer immunotherapy and are committed to make a difference in the lives of more cancer patients.
Tessa’s R&D is based on over three decades of research and development by our Scientific Co-Founder, and internationally recognized clinical scientist, Dr. Malcolm Brenner. His research has shown that the body’s anti-viral immune response can be harnessed as a potent therapy for cancer treatment. Our core platform technology uses a specific subset of immune cells known as Virus-Specific T cells (VSTs) – it has shown compelling results in the treatment of solid tumors in clinical trials.
We have a rapidly growing pipeline of autologous and allogeneic therapies that combine VSTs with other immune-oncology approaches to target multiple tumor indications.
A Multi-Country, Multi-Site Production and Supply Chain Network
Building robust, scalable operational capabilities is a critical aspect of our strategy to deliver cell therapies to patients worldwide – promptly and reliably.
Bolstered by a global production and supply chain footprint, and a strong clinical trial network, our cell therapies are delivered to patients in 30 clinical sites across 5 countries today. Till date, Tessa has successfully delivered over 150 autologous cell therapy lots in a Phase III clinical trial setting.
Tessa plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia. The state-of-the-art facility will enable us to deliver our cell therapies faster and more reliably, to thousands of cancer patients annually worldwide. It will be built to run both clinical and commercial manufacturing of cell therapy products that is compliant with current Good-Manufacturing-Practice (cGMP) guidelines from the U.S. Food and Drug Administration, European Medicines Agency and key regulators in Asia. Read more about our upcoming facility here.
A Global Clinical Trial Network for Accelerated Trial Roll-outs
Together with our academic, clinical, and scientific research partners, Tessa has established a fully integrated approach to the treatment of cancer with immunotherapy.
Our clinical trial partners include leading institutions in the United States, such as the Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center, Baylor College of Medicine, Baylor Scott & White Health, as well as other Centers of Excellence in Massachusetts, Texas, and California.